The closing price of Legend Biotech Corp ADR (NASDAQ: LEGN) was $60.03 for the day, down -4.44% from the previous closing price of $62.82. In other words, the price has decreased by -$2.79 from its previous closing price. On the day, 1454530 shares were traded.
Ratios:
Our analysis of LEGN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.83 and its Current Ratio is at 6.92. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on March 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $86.
On November 06, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $90.09.Goldman initiated its Buy rating on November 06, 2023, with a $90.09 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 10.92B and an Enterprise Value of 9.94B. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.27 while its Price-to-Book (P/B) ratio in mrq is 8.15. Its current Enterprise Value per Revenue stands at 34.86 whereas that against EBITDA is -20.80.
Stock Price History:
Over the past 52 weeks, LEGN has reached a high of $77.32, while it has fallen to a 52-week low of $43.35. The 50-Day Moving Average of the stock is 60.97, while the 200-Day Moving Average is calculated to be 65.21.
Shares Statistics:
LEGN traded an average of 965.16K shares per day over the past three months and 1.46M shares per day over the past ten days. A total of 181.79M shares are outstanding, with a floating share count of 180.01M. Insiders hold about 0.98% of the company’s shares, while institutions hold 46.99% stake in the company. Shares short for LEGN as of Feb 29, 2024 were 10.26M with a Short Ratio of 10.63, compared to 10.05M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.63% and a Short% of Float of 10.80%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.32 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.73, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.09 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$0.5 and -$2.74 for the fiscal current year, implying an average EPS of -$1.51. EPS for the following year is -$0.63, with 9 analysts recommending between $0.42 and -$1.71.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $202.5M to a low estimate of $87.5M. As of the current estimate, Legend Biotech Corp ADR’s year-ago sales were $36.34M, an estimated increase of 377.60% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $145.75M, an increase of 98.80% less than the figure of $377.60% in the same quarter last year. There is a high estimate of $209.8M for the next quarter, whereas the lowest estimate is $100M.
A total of 15 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $701.9M, while the lowest revenue estimate was $450M, resulting in an average revenue estimate of $610.38M. In the same quarter a year ago, actual revenue was $285.14M, up 114.10% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $1.11B in the next fiscal year. The high estimate is $1.53B and the low estimate is $857.5M. The average revenue growth estimate for next year is up 82.40% from the average revenue estimate for this year.
